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Glucose produced by gluconeogenesis and glycogenolysis plays an important role in aggravating hyperglycemia in diabetes,
and altered mitochondrial function is associated with impaired energy production. The present study focuses on the eﬀect
of Semecarpus anacardium on carbohydrate metabolism and energy production in diabetic rats. Diabetes was induced by the
administration of Streptozotocin at a dose of 50mg/kg.b.wt. Three days after the induction, Semecarpus anacardium at a dose of
300mg/kg.b.wt was administered for 21 days. After the experimental duration, the activities of the enzymes involved in Glycolysis,
TCA cycle, gluconeogenesis, and glycogen were assayed in the liver and kidney of the experimental animals. In addition, to the
complexes the protein expression of AKT and PI3K were assayed. The levels of the enzymes involved in Glycolysis and TCA cycle
increased, while that of gluconeogensis decreased. The activities of the mitochondrial complexes were also favorably modulated.
The expressions of PI3K and AKT also increased in the skeletal muscle. These eﬀects may be attributed to the hypoglycemic and
the antioxidative activity of Semecarpus anacardium. The results of the study revealed that Semecarpus anacardium was able to
restore the altered activities of the enzymes involved in carbohydrate metabolism and energy production.
1.Introduction
Diabetes mellitus is a metabolic disorder characterized by
hyperglycemia due to defect in insulin secretion, action, or
both. Liver plays an important role in the glucose home-
ostasisthroughglycolysis,glycogenesis,andgluconeogenesis.
The net glucose uptake by the liver depends on the activities
of glucokinase and glucose 6 phosphatase. The activity of
hepatic glucokinase is markedly decreased and activity of
glucose-6-phosphatase is almost doubled [1]. Glucose, taken
up by secondary active transporter proteins, is degraded
to pyruvate, which is then introduced into the citric acid
cycle after its decarboxylation to acetyl coenzyme A. The
Krebs cycle provides NADH for oxidative phosphorylation
to generate the electron gradient for ATP formation.
Medicinal plants have played a signiﬁcant role in various
ancient traditional systems of medicine. They are rich sou-
rces of bioactive compounds and thus serve as impor-
tant raw materials for drug production and have become
a target for the search of new drugs [2]. Semecarpus
anacardium L. (Anacardiaceae) (SA) commonly known as
Bhallataka or marking nut is used in indigenous systems of
medicine for the treatment of various diseases [3]. Many
compounds mainly biﬂavonoids, phenolics, bhilawanols,
sterols, Anacardic acid, and glycosides have been identiﬁed
as constituents of S. anacardium nut extract. On the basis
of chemical and spectral data, several biﬂavonoids, such
as Jeediﬂavanone, Galluﬂavanone, Nalluﬂavanone, Semecar-
petin, and Anacardiﬂavanone have been characterized [4].
Several monophenolic compounds known as Semecarpol
(C17H28O) and Bhilawanol were also isolated [5]. The
drug is used as milk extract to treat many diseases as
detailed by many texts specially Caraka Samhita [6]. Earlier
studies from our laboratory have proved the presence of2 Evidence-Based Complementary and Alternative Medicine
Table 1
Group I Control animals—Normal healthy controls received olive oil (0.5mL) orally by gastric intubation for 21 days daily
Group II Diabetes induced—(50mg/kg b.wt.) Streptozotocin dissolved in 0.5mL of 0.1M citrate buﬀer PH 4.5.
Group III SA treated—Three days after the induction of diabetes, SA (300mg/kg body weight dissolved in 0.5mL olive oil)
was administered by gastric intubation for 21 days daily.
Group IV Metformin treated—Three days after the induction of diabetes Metformin (500mg/kg body weight dissolved in
0.5mL physiological saline) was administered by gastric intubation for 21 days daily.
Group V Drug control—Animals received SA at a dose of 300mg/kg b. wt. in olive oil (0.5mL) orally by gastric intubation
for 21 days daily.
p o l yp h e n o l si nt h en u tm i l ke x t r a c t[ 7]. TLC, HPLC, and
HPTLC analysis of the nut and milk extract conﬁrmed the
presence of the above compounds [8–11] .T h ek e r n e lo i l
contains oleic acid, 60.6; linoleic acid, 17.1; palmitic acid,
16; stearic acid, 3.8; arachidic acid, 1.4%. Studies have also
reported that the drug has anti-inﬂammatory, antiarthritic,
anthelmentic, antioxidative and anticancer activity [12,
13]. The nut milk extract has anticancer, hepatoprotective
activity, anti-inﬂammatory, antioxidant property [14], and
hypoglycemic activity [15]. Since Insulin suppresses hepatic
glucoseoutputbystimulatingglycogensynthesisandinhibit-
ing glycogenolysis and gluconeogenesis, a drug that would
stimulate the insulin production or sensitize the peripheral
tissues to insulin would be of beneﬁcial eﬀect to treat
DiabetesMellitus.Theholisticmedicalapproachprovidedby
traditional medicine prompted us to undertake the present
study to prove the eﬀect of SA on the altered activities of
carbohydrate-metabolizing enzymes and energy production
in diabetic rats. The eﬀect of SA on the expression of PI3K
and AKT was also investigated.
2.MaterialandMethods
Male Albino rats of Wister strain weighing 260 ± 10g
were used in this study. The animals were housed in
polypropylene cages under a control environment with 12h
light/dark cycles and a temperature between 27 and 37
◦C
and were given a commercial diet with water ad libitum. All
experiments involving animals were conducted according to
NIH guidelines, after obtaining approval from the Madras
Institute’s Ethical Committee IEAC no 02/075/06. The milk
extract of SA was prepared according to the Formulary of
Siddha Medicine, by boiling the nuts (200g) with 500mL
milk. Decanting the decoction, 500mL of milk was added
to the boiling nuts and again boiled for some time. The
decoction was recovered and the process was repeated again
with the milk (500). All the three portions of milk nut
decoction were mixed with ghee (1.5kg) and boiled till
dehydration. Then it was ﬁltered and stored. Olive oil was
used as a vehicle for the suspending of the extract and
administering to rats [16].
3.ExperimentalDesign
Male albino Wister rats weighing 250–270g were divided
into ﬁve groups of six animals each (see Table 1).
3.1. Biochemical Analysis. After the experimental period,
the animals were killed by cervical decapitation. The liver,
kidney, and skeletal muscle were excised immediately and
immersed in ice-cold physiological saline. Ten per cent
homogenate was prepared with fresh tissue in 0.01M Tris-
HCl buﬀer (pH 7.4) and was used for the following assays.
Hexokinase was assayed by the method of Brandstrup
et al. [17]. Phosphogluco-isomerase was assayed by the
method of Horrocks et al. [18]. Phosphofructokinase was
assayed kinetically by the method of Reinhart and Lardy
[19]. Aldolase was estimated by the method of King [20].
LDH was assayed by the method of King [21]. Glucose-
6-Phosphate Dehydrogenase was assayed by the method of
Beutler and West [22]. Glucose-6-phosphatase and Fructose
1, 6-bisphosphatase were assayed according to the method of
J. M. Gancedo and C. Gancedo [23]. Glycogen in liver and
kidney was estimated by the method of Morales et al. [24].
Mitochondria were isolated by the method of Johnson
et al. [25]. Isocitrate Dehydrogenase was assayed according
to the method of [20]. The activity of SDH was assayed
according to the method of Slater and Borner Jr. [26]. Malate
Dehydrogenase was assayed by the method of Mehler et
al. [27]. α-ketoglutarate dehydrogenase was assayed by the
method Reed and Mukherjee [28]. Complex I activity was
measuredbyfollowingthedecreaseinabsorbanceduetooxi-
dation of NADH to NAD at 340 with 425nm as the reference
wavelength by the method of Hateﬁ [29]. Complex II activity
was measured by following the decrease in absorbance
due to coupled reduction of 2,6-dichlorophenolindophenol
(DCPIP) at 60mM with 750nm as the reference wavelength
[30]. Complex III activity was measured by following the
increase in absorbance due to reduction of ferricytochrome
c at 550 with 580nm as the reference wavelength (ε =
19mM−1 cm−1)[ 31]. Complex IV activity was measured by
following the oxidation of cytochrome c Fe2+ [32].
3.2. Western Blot Analysis of PI3K and AKT in Skeletal Muscle
of Control and Experimental Animals. The protein concen-
tration of the skeletal muscle for PI3K, AKT was estimated
and the samples (equal amount of protein; 50μg) were
boiled with sample solubilizing buﬀer (SSB) for 5min and
separated on 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS–PAGE). The gel was transferred
ontoanitrocellulosemembrane(HybondC+,Amershamlife
sciences) at 30V for 5h. Membrane was then washed thrice
with PBS and blocking was done with TBST buﬀer (20mMEvidence-Based Complementary and Alternative Medicine 3
Tris, 500mM NaCl, and 0.1% Tween 20, pH 7.5) containing
5% nonfat dry milk. Then, the membrane was incubated
with primary antibody (rabbit polyclonal anti-PI3K) and
AKT (mouse) in TBST buﬀer containing 1% nonfat dry
milk and agitated gently at room temperature for 3h.
After incubation with the primary antibody, the blots were
washed thrice for 5min with TBST buﬀer and incubated
for 75min at room temperature with horseradish peroxidase
(HRP) conjugated secondary antibody (1:500 dilutions) in
phosphate-free TBST buﬀer containing 5% nonfat dried
milk.ThebandsweredetectedusingDAB/hydrogenperoxide
chromogen system.
3.3. Statistical Analysis. T h ev a l u e sa r ee x p r e s s e da sm e a n
± SD for six rats in each group. Statistically signiﬁcant
diﬀerences between the groups were calculated using one-
way analysis of variance (ANOVA), followed by student-
Newman-Keuls for multiple comparisons using statistical
package for social sciences (SPSS) computer package. Values
of P<. 05 were considered to be signiﬁcant.
4. Results
4.1. Activities of Glycolysis and Gluconeogenic Enzymes. The
activities of the carbohydrate-metabolizing enzymes in liver
and kidney are given in Figures 1(a) and 1(b).I nG r o u pI I
animals, there was a signiﬁcant decrease (P<. 05) in the
activities of Hexokinase, phosphoglucoisomerase, and phos-
phofructokinaseintheliverandkidney.Thevaluesdecreased
by 38% for hexokinase, 33.6% for phosphoglucoisomerase,
and 39.5% for phosphofructokinase in liver, and in the kid-
neytheactivitiesdecreasedby44.4%forhexokinase,27%for
phosphoglucoisomerase, and 39% for phosphofructokinase.
These were signiﬁcantly increased (P<. 05) upon drug
administration (Group III and Group IV).
The activities of aldolase increased (P<. 05) signiﬁcantly
inuntreateddiabeticanimals(GroupII)whichwerereverted
back to near normal levels upon SA (Group III) and
Metformin (Group IV) treatment. A marked decrease in
the activity of G6PDH was seen in the liver and kidney for
Group II animals. In liver, the activity decreased by 57.5%,
and in kidney, the activity decreased by 29.1%. These were
signiﬁcantly increased (P<. 05) in the SA and Metformin-
treated groups (Group III and Group IV). Nonsigniﬁcant
values were obtained when Group I and Group V animals
were compared.
The activities of Fructose 1,6 bis phosphatase (FBPase)
and glucose-6-phosphatase (G-6pase) increased in liver and
kidney of diabetic untreated animals (Group II). There was
1.92-foldincreaseinFBPaseinliverandG-6Paseincreasedby
1.3-fold. In the kidney, the fold increase was 1.7 and 1.3 for
both the enzymes, respectively. These decreased signiﬁcantly
(P<. 05) upon SA and Metformin treatment.Nonsigniﬁcant
values were obtained when the the Metformin treated
(Group IV) and and SA treated (Group III) were compared.
No signiﬁcant changes were obtained when Group I and
Group V animals were compared.
The glycogen content was found to be decreased in the
liver (P<. 05) and increased (P<. 05) in the kidney
of Group II diabetic animals. These were reverted back to
near normal levels on administration of SA. When Group
III and Group IV animals were compared, SA was found to
be more eﬀective than Metformin. No signiﬁcant changes
w e r eo b s e r v e dw h e nG r o u pIa n dG r o u pVa n i m a l sw e r e
compared.
The activities of LDH increased (P<. 05) signiﬁcantly in
untreated diabetic animals (Group II) which were reverted
back to near normal levels upon SA (Group III) and
Metformin (Group IV) treatment (Figure 2).
4.2. Modiﬁcation of Energy Production by SA. The eﬀects of
SA and Metformin on the activities of TCA cycle enzymes in
the kidney and liver are given in Figures 3(a) and 3(b).I n
Group II animals, the activities of ICDH, αKGDH, SDH, and
MDH were found to be decreased in the liver and kidney.
The decrease for ICDH was 19.5% in liver and 16.2% in
kidney, αKGDH; 35.4% and 34.6% in liver and kidney, SDH;
29.9% and 34.6% for liver and kidney, and for MDH it was
30% and 26% for liver and kidney, respectively. These values
were signiﬁcantly increased (P<. 05) in Group III and
G r oupIVanimals.W henG r oupIandG r oupVanimalsw er e
compared, nonsigniﬁcant values were obtained.
In untreated diabetic animals (Group II), marked inhi-
bition (P<. 05) of the activities of mitochondrial complexes
wasfoundasshowninFigures4(a)and4(b)whencompared
to normal animals. These were restored to near normal levels
(P<. 05) upon drug administration (Group III and Group
IV). No signiﬁcance was found when control (Group I) and
drug control group (Group V) animals were compared.
4.3. SA Increases the Protein Expression on PI3K and AKT in
theSkeletalMuscleofControlandExperimentalAnimals. The
protein expressions of AKT and PI3K are shown in Figures
5 and 6. In Group II animals, there was decrease in protein
expression of PI3K and AKT when compared to Group
III, indicating the insuﬃciency of insulin to maintain the
normal signaling and the uptake of glucose through GLUT4
in the muscles of the animals which results in hyperglycemia.
After treatment of the animals with SA, increase in protein
expression was seen.
5. Discussion
Liver plays a key role in the maintenance of glucose
homeostasis. Following a carbohydrate rich meal, it removes
a major part of the excess glucose that is absorbed and
releases it in between meals during starvation and exercise
[33]. The glucostat function of the liver is based on the
reversible shift between glycogen synthesis and degradation
as well as between glycolysis and gluconeogenesis.
The reaction catalyzed by hexokinase serves as the entry
point for glucose into glycolysis, glycogen synthesis, and
the hexose monophosphate. Inhibition of hexokinase leads
to impaired oxidation of glucose via glycolysis, resulting in
hyperglycemia and decreased ATP production [34]. High
glucose concentration nonenzymatically glycates phospho-
glucoisomerase and inhibits the proportion of glucose 6-
phosphate metabolized via the glycolytic pathway. Insulin4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: (a) Glycolytic and gluconeogenic enzymes in liver of control and experimental animals. Units: Hexokinase—nmoles of glucose-
phosphate liberated/min/mg protein, Phosphoglucoisomerase—nmoles of fructose liberated/min/mg protein, Phosphofructokinase—
nmoles of substrate formed/min/mg protein, Aldolase—nmoles of glyceraldehyde liberated/min/mg protein, Glucose 6-phosphatase—
nmoles of phosphorous liberated/min/mg protein, Fructose-1,6-diphosphatase—nmoles of phosphorous liberated/min/mg protein.
Glycogen—mg/g tissue. Values are expressed as mean ± SD for six animals. Comparisons are made between “a”—Group II versus
Group I, “b”—Group III and IV versus Group II, “c”—Group IV versus Group III, and “d”—Group V versus Group I. The symbol
∗ represents the statistical signiﬁcance at P<. 05, NS—Nonsigniﬁcant. (b) Glycolytic and gluconeogenic enzymes in the kidney of
control and experimental animals. Units: Hexokinase—nmoles of glucose-phosphate liberated/min/mg protein, Phosphoglucoisomerase—
nmoles of fructose liberated/min/mg protein, Phosphofructokinase—nmoles of substrate formed/min/mg protein, Aldolase—nmoles
of glyceraldehyde liberated/min/mg protein, Glucose 6-phosphatase—nmoles of phosphorous liberated/min/mg protein, Fructose-1,6-
diphosphatase—nmoles of phosphorous liberated/min/mg protein. Glycogen—mg/g tissue.Values are expressed as mean ± SD for six
animals. Comparisons are made between “a”—Group II versus Group I, “b”—Group III and IV versus Group II, “c”—Group IV versus
Group III, and “d”—Group V versus Group I. The symbol ∗ represents the statistical signiﬁcance at P<. 05, NS—Nonsigniﬁcant.Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: LDH activity in the liver and kidney of control and
experimental animals. Lactate dehydrogenase—μmoles of pyruvate
formed/min/mg protein.
inﬂuences the intracellular utilization of glucose by increas-
ing the activity and amount of several key enzymes including
glucokinase and phosphofructokinase. Increased Aldolase
seenin untreateddiabetic ratsmay bedueto cellimpairment
and necrosis. Administration of SA enhanced the uptake of
glucose and increased glycolysis [35]. Oxidative stress seen
in diabetes may be responsible for the increase in LDH. The
release of LDH reﬂects a nonspeciﬁc alteration in the plasma
membrane integrity and/or permeability as a response to
STZ. The decreased level of LDH in SA-treated group is
due to the presence of poly phenols which have strong
antioxidative property [14]. Insulin increases Glucose-6-
phosphate dehydrogenase (G6PDH) activity of rat liver
cells, while high glucose inhibits it. The observed decrease
in G6PDH activities may be due to the reduced insulin
secretion and action, or inhibition of this enzyme due to
phosphorylation or oxidative modiﬁcation. G6PDH protects
the cell from death, which is inactivated by lipoperoxidation
products such as 4-hydroxy-2-nonenal [36]. SA increases the
activity of G6PDH in the Group III animals by decreasing
the lipid peroxidation [35]. The elevated hepatic glucose
production (HGP) seen in Group II animals is due to
increased rate of gluconeogenesis rather than glycogenolysis
[37]. In Type I Diabetes, the mRNA levels of Glucose
6 phosphatase catalytic subunit and activity are increased
which lead to increased HGP [38]. Increased hepatic glucose
production in Diabetes Mellitus is also associated with
impairedsuppressionoffructose-1,6-bisphosphatase[39].In
the diabetic state, the activities of the glycolytic enzymes are
decreased with increase in gluconeogenic enzymes as seen
in Group II animals. These were eﬀectively reverted back to
near normal levels upon administration of SA [40]. The low
glycogen content in diabetic rat liver could increase glucose
uptake and hexokinase activity, resulting in an increase
in intracellular Glucose 6 phosphate concentration and
consequently in an increase in Glycogen synthase activity.
The renal hypertrophy observed is closely correlated with the
degree of hyperglycemia. It is possible, therefore, that there
might have been the breakdown of this glycogen that could
have contributed to the increase in renal glucose release [41].
Glucose metabolism, the citric acid cycle, and oxidative
phosphorylation are central biochemical pathways in cellular
energy metabolism. Hyperglycemia glycates ICDH which
results in reduced activity [42]. α-KGDH could be a crucial
target of reactive oxygen species (ROS) and being an
important regulatory site in the mitochondrial metabolism
could play a key role in the bioenergetic deﬁcit evolving
oxidativestress.Oneofthemitochondrialproteinsselectively
targetedby4-Hydroxynonenal(HNE)istheFAD-containing
subunit of SDH. This result is in good agreement with
the decrease in oxygen consumption in the presence of
succinate and in complex II activity as reported by Lashin
et al. [43]. The decreased activities of the citric acid cycle
enzymes in diabetic rats were brought back to near normal
levels upon administration of the drug, which may be due
to the positive modiﬁcation of the SDH subunit [44]a n d
its hypoglycemic eﬀect [45]. Many of the ETC complex
subunits appear to be speciﬁc targets for ROS-mediated
oxidative modiﬁcations. Mitochondria isolated from Type
I Diabetic rats showed decreased respiratory chain activity
characterized by decreased membrane potential, decreased
expression of oxidative phosphorylation genes, and respira-
tory ratios. The mRNAs for Complex I, II, III, and IV were
also found to be decreased [46]. Munusamy et al. reported
kidney mitochondrial impairment in diabetes. The decline
in renal mitochondrial respiration is due to increased ROS
production at complexes I, III, and IV [47]. SA normalized
the activities of the complexes and decreased the production
of superoxide due to its radical scavenging activity, which
may be attributed to the ﬂavonoids and other constituents
present in the drug.
Membrane-associated signaling processes are a critical
part of the complex pathways that transduce insulin-
mediated change in cellular metabolism. After insulin binds
to its receptor, activation of at least two major pathways, one
involving a ras/mitogen-activated protein kinase (MAPK)
cascade and the other involving phosphatidylinositol-3-
kinase(PI3-kinase)takesplace.PI3-kinaseiswellrecognized
as an important step in the insulin signaling pathway to
glucose transport through GLUT4 translocation [48].
Activated PI3K activates downstream component Akt
(PKB). Overexpression of constitutively active AKT directly
promotes glucose transport and translocation of GLUT1
and GLUT4 to the plasma membrane. Insulin increases
the association of AKT with GLUT4-containing vesicles.
Increased expression of PI3K and AKT in the SA-treated
group may be due to the presence of polyphenols since they
have been implicated in mediating glucose transport in vitro
and in vivo studies [49].
The protective eﬀect of SA may be due to its antiox-
idative [14] and hypoglycemic activity [45]. These could
be attributed to the presence of ﬂavonoids. Flavonoids6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: (a) Activities of Citric acid cycle enzymes in liver of control and experimental animals. Units: ICDH—nmol of α-ketoglutarate
liberated/min/mg protein, α-KDH—μmol of ferrocyanide liberated/min/mg protein, SDH—μmol of succinate oxidized/min/mg protein,
MDH—nmol of NADH oxidized/min/mg protein. Values are expressed as mean ± SD for six animals. “a”—Group II versus Group I,
“b”—Group III and IV versus Group II, “c”—Group IV versus Group III, “d”—Group V versus Group I. The symbol ∗ represents the
statisticalsigniﬁcanceatP<. 05,NS—Nonsigniﬁcant.(b)ActivitiesofCitricacidcycleenzymesinliverofcontrolandexperimentalanimals.
Units: ICDH—nmol of α-ketoglutarate liberated/min/mg protein, α-KDH—μmol of ferrocyanide liberated/min/mg protein, SDH—μmol
ofsuccinateoxidized/min/mgprotein,MDH—nmolofNADHoxidized/min/mgprotein.Valuesareexpressedasmean ±SDforsixanimals.
“a”—Group II versus Group I, “b”—Group III and IV versus Group II, “c”—Group IV versus Group III, “d”—Group V versus Group I. The
symbol ∗ represents the statistical signiﬁcance at P<. 05, NS—Nonsigniﬁcant.
are a group of ubiquitously distributed plant polyphenols
which exhibit a wide range of pharmacological eﬀects. The
inhibition of lipid peroxidation is due to the free radical
scavenging property of ﬂavonoids. They scavenge free radical
by donating their hydrogen groups and prevent the initiation
of chain reaction. They also scavenge singlet O2, terminating
peroxides by their low redox potential [50]. They also reduce
lipid peroxidation by reducing the levels of malondialdehyde
and conjugated dienes [51]. The antioxidative activity of
the SA is due to the presence of ﬂavonones, present in the
drug which contains a catechol moiety in the B ring. In
the Galluﬂavanone, the catechol moiety in the secondary
ﬂavanone ring also confers the antioxidant property. The
4-oxo group present in all the biﬂavanones in SA contributes
to the free radical quenching activity. The 5-OH and 7-
OH groups present in Jeediﬂavanone also confer scavenging
potential. Semecarpuﬂavanone, Semecarpetin, and Galluﬂa-
vanone have a 7-OH group that might contribute to the free
radical-chelating activity of SA [52].
6. Conclusions
From the above observations it can be concluded that SA
is able to favorably modulate the activities of the enzymes
involved carbohydrate metabolism. It was also able to
restore the altered activities of the TCA cycle enzymes andEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: (a) Eﬀect of SA on the activities of mitochondrial complexes in liver of control and experimental animals. Values are expressed
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Lane 1 Lane 2 Lane 3 Lane 4 Lane 5
60kDa (AKT)
Figure 5: Western blot analysis of AKT in skletal muscle of control
andexperimentalanimals.Lane1—control,Lane2—induced,Lane
3—SA treated, Lane 4—Metformin treated, Lane 5—drug control.
normalize the alteration in energy production and increase
the expression of PI3K and AKT in the skeletal muscles
leading to increase in the uptake of glucose by the cells.
Lane 1 Lane 2 Lane 3 Lane 4 Lane 5
85kDa (PI3K)
Figure 6:WesternblotanalysisofPI3Kinskeletalmuscleofcontrol
andexperimentalanimals.Lane1—control,Lane2—induced,Lane
3—SA treated, Lane 4—Metformin treated, Lane 5—drug control.
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